Business

Lakeside Announces Fiscal 2025 Third Quarter and Nine-Month Results

ITASCA, IL, May 15, 2025 (GLOBE NEWSWIRE) -- Lakeside Holding Limited (“Lakeside” or the “Company”) (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market operating through two specialized subsidiaries—American Bear Logistics and Hupan Pharmaceutical (Hubei) Co., Ltd., today announced financial results for its fiscal 2025 third quarter and nine months ended March 31, 2025. Management Commentary "The third quarter and first nine mont

articleLakeside Holding LimitedMay 15, 202518/company/lakeside-holding-limited-common-stock/news/lakeside-announces-fiscal-2025-third-quarter-and-nine-month-results
Lakeside Announces Fiscal 2025 Third Quarter and Nine-Month Results

About this update from Lakeside Holding Limited

[{"type":"text","content":"ITASCA, IL, May 15, 2025 (GLOBE NEWSWIRE) -- Lakeside Holding Limited (“Lakeside” or the “Company”) (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market operating through two specialized subsidiaries—American Bear Logistics and Hupan Pharmaceutical (Hubei) Co., Ltd., today announced financial results for its fiscal 2025 third quarter and nine months ended March 31, 2025.","length":439,"tagName":"p"},{"type":"text","content":"Management Commentary","length":21,"tagName":"p"},{"type":"text","content":""The third quarter and first nine months of fiscal 2025 presented a dynamic environment for Lakeside," commented Henry Liu, Chief Executive Officer. "While our established cross-border freight solutions experienced revenue declines compared to the prior year, primarily due to shifts in global shipping demands and pricing pressures, we are encouraged by the initial contributions from our new pharmaceutical distribution segment following the Hupan Pharmaceutical acquisition.","length":492,"tagName":"p"},{"type":"text","content":"Our strategic objectives remain clear: expand our footprint in China's pharmaceutical distribution market, where significant growth opportunities exist, while continuing to optimize our cross-border logistics services. We are actively integrating Hupan Pharmaceutical into our operations to leverage synergies between business segments.","length":340,"tagName":"p"},{"type":"text","content":"Despite challenging market conditions in the freight sector, we remain committed to diversifying revenue streams and investing in high-growth areas. We believe our strategic focus on the Asia-Pacific market, coupled with our expansion into the pharmaceutical sector, positions Lakeside for long-term shareholder value creation."","length":333,"tagName":"p"},{"type":"text","content":"Highlights for the Nine Months Ended March 31, 2025, and Recent Developments:","length":77,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Successful Initial Public Offering (IPO): On July 1, 2024, the Company successfully closed its IPO of 1,500,000 shares of common stock at $4.50 per share, raising aggregate gross proceeds of approximately $6.75 million (net proceeds of approximately $5.4 million after deducting underwriting discounts,...

More updates from Lakeside Holding Limited

Lakeside Holding Limitedthe CompanyLakesidenine monthsHupan Pharmaceuticalfreight solutionsAsia-Pacific marketpharmaceutical productscross-border